Advances in genetic engineering have created opportunities for improved understanding of the molecular basis of carcinogenesis. Through selective introduction, activation, and inactivation of specific genes, investigators can produce mice of unique genotypes and phenotypes that afford insights into the events and mechanisms responsible for tumor formation. It has been suggested that such animals might be used for routine testing of chemicals to determine their carcinogenic potential because the animals may be mechanistically relevant for understanding and predicting the human response to exposure to the chemical being tested. Before transgenic and knockout mice can be used as an adjunct or alternative to the conventional 2-year rodent bioassay, information related to the animal line to be used, study design, and data analysis and interpretation must be carefully considered. Here, we identify and review such information relative to Tg.AC and rasH2 transgenic mice and p53 +/-and XPA -/knockout mice, all of which have been proposed for use in chemical carcinogenicity testing. In addition, the implications of findings of tumors in transgenic and knockout animals when exposed to chemicals is discussed in the context of human health risk assessment.
INTRODUCTION
Carcinogenicity testing guidelines for safety evaluation and regulatory application have been in effect, largely unmodified, for more than 25 years (11, 139 ). The concept of carcinogenicity testing in 2 rodent species was initiated in part in response to concern about identifying potential human health risks associated with exposure to new chemicals in the environment (11) . The basic study design consists of lifetime (=24 months) exposure of rats and mice to compounds of interest (57) . Daily exposure is achieved by incorporating the chemical into the animals' feed or water. When administered by oral gavage, parenterally, or by dermal application, exposure is typically limited to 5 d/wk. In pharmaceutical compound test-ing, such exposures occur daily. Different groups of animals are exposed to different doses of the test chemical. The incidence, type(s), and location(s) of treatment-associated tumors are used to establish human cancer risk.
The value of the rodent bioassay for determining the potential of chemicals to cause cancer in humans has been the subject of continuing debate since its introduction. Points of concern include appropriate study design, dosing, and the biologic relevance of the test results for humans. Uncertainties are associated with the determination and application of the highest dose to be tested, ie, the maximum tolerated dose, the significance and interpretation of both reduced and increased tumor incidence among chemical-exposed animals, and the value of performing lifetime studies in 2 species (3, 26, 88, 96) . Disparities between inventories of known rodent carcinogens and those of known human carcinogens as determined by the International Agency for Research on Can-cer underscore the uncertainty about the relevance of the rodent bioassay (11, 88, 123) . Extrapolation from cancercausing (typically high) doses in rodents to the likely low dose exposures of humans is fraught with uncertainty. Such concerns are further confounded by uncertainty about the implications of single chemical exposures of inbred animals relative to the multiple and variable exposures of outbred humans to chemicals in the environment, workplace, and home (11, 88, 123) . The debate around these and related issues in spite of more than 25 years of experience encompassing more than 500 chemicals reflects a collective desire to develop new, improved approaches to identifying, with precision, accuracy, and confidence, those chemicals that pose a possible or probable human cancer risk.
Interest in alternatives to conventional rodent bioassays for assessing the carcinogenic potential of chemicals to which humans may be exposed crystalized during a meeting of the International Conference on Harmonisation Expert Working Group on Safety. Representatives from the pharmaceutical industry and from drug regulatory agencies around the world acknowledged the limited utility of conventional studies and proposed a new approach to carcinogenicity testing of pharmaceutical compounds (70) . The proposal calls for a single 2-year carcinogenicity bioassay in a single rodent species and a shortor mediumterm in vivo assay with a tumor endpoint. Transgenic mouse lines were suggested as possible shortor medium-term assay vehicles. In subsequent notices, experimental approaches to evaluating the carcinogenic potential of pharmaceutical compounds to humans (71) and testing guidelines that included provision for a second conventional bioassay in a second rodent species (72) were described.
Advances in genetic engineering during the 1980s and 1990s have resulted in the predictable insertion, activation, or inactivation of selected genes, including oncogenes and tumor suppressor genes, within the rodent genome. Through the use of specific molecular constructs, gene expression or inactivation may be limited to selected tissues. Introduced genes (transgenes) result in the expression of novel gene products or in the overexpression of an endogenous gene product. Genes that are selectively inactivated (knocked out), give rise to animals that no longer express normal amounts of the specific gene product. Both transgenic and knockout animals can be used to study the genetic and molecular basis for carcinogenesis and may contribute to improving the scientific basis for human cancer risk assessment (100, 123, 127) . The allure of using transgenic animals for carcinogenicity testing is a reflection of the ability to introduce or modulate genes associated with specific human tumors. Through the creation of animal models that mimic the molecular changes observed in human cancers, the relevance of the animal models for humans should be enhanced. Similarly, such models should yield more reproducible and reliable data than are currently available and could reduce overall animal use, save time, and be more cost effective in the context of carcinogenicity testing.
Currently, few data are available on the carcinogenic responses of transgenic and knockout animals exposed to chemicals. Similarly, there is limited information concerning the use of such animals for carcinogenicity testing, and the absence of an appreciable historic database, particularly for known rodent and human carcinogens, confounds evaluation of the outcomes of such studies. In addition, issues such as the availability of animals, animal standardization (assuring transgene insertion and stability), animal maintenance and study costs, and determination of optimal study design (eg, dose and route of exposure, study duration) need to be resolved.
Here we review scientific issues related to the development, use, and application of transgenic and knockout animals for carcinogenicity testing and the implications of these studies for human health risk assessment. The report will focus on those lines of transgenic and knockout mice that have been suggested for possible use in routine carcinogenicity testing, ie, the Tg.AC, p53+1-heterozygote, rasH2 heterozygote, and XPA-1-mice. Characteristics of each of these lines and the justification for their proposed use in carcinogenicity testing is reviewed. The design of carcinogenicity studies using such animals is explored, and the interpretation of findings from such studies is discussed. Although the focus is on these 4 mouse lines, as other transgenic and knockout animal lines are developed, similar issues will need to be considered in the quest to improve the scientific basis for carcinogenicity risk assessment.
BACKGROUND Derivation and Phenotypic Properties of Inbred Strains for Transgenic Animal Development
Routine carcinogenicity testing in mice is typically performed in Swiss-derived CD animals and in the socalled NTP mouse, the F, progeny obtained from crossing female C57BL/6 and male C3H/HeN-MTV-mice (51). This hybrid animal, the B6C3F1 mouse, is the principal subject of carcinogenicity testing conducted in accord with the protocols of the US National Toxicology Program (NTP). Conversely, mice used in most other biomedical research applications, including transgenic animal development, represent inbred strains, eg, C57BL/6, C3H/He, BALB/c, A/J, 129 Sv, and FVB/N. Inbreeding through successive brother-sister matings for -20 generations results in progeny that are >99% identical and are homozygous at all loci (22) . Inbreeding offers the experimentalist 2 advantages. First, because all individuals of a given strain are identical, each should respond similarly to specific stimuli or investigational protocols, thus reducing interanimal variability and reducing the number of animals required to yield statistically relevant data (51) . Second, many of the inbred mouse strains currently available were established to fix or stabilize the expression of a specific allele or mutation. Each inbred strain expresses and maintains a specific genotype that is often reflected by a stable phenotype, eg, coat color, specific disease resistance or susceptibility, enzyme polymorphism, or spontaneous tumorigenesis. Specific inbred mouse strains thus can offer useful models for understanding particular disease or biologic processes. In developing transgenic animals, factors such as reproductive traits, aggressiveness, coat color genetics, and the possibility of sex-linked expression of specific phenotypes are important when determining the strain(s) of mice to be used for the initial gene manipulation and the subsequent backcrossing. It is important to define the genetic background of both the transgenic and nontransgenic mice that will serve as control animals during testing. This requires identification and/or creation of the appropriate wild-type control animal that matches the genetic background of the knockout mouse. Knowledge of the frequency of specific spontaneous pathologies, eg, neoplasias, associated with each parental strain and the resulting line is useful in interpreting experimental results (94) . Similarly, the animals of the resulting line may respond differently to chemical exposure than animals of either parental strain (106) . Because the mouse strains that are currently used for genetic manipulation typically have not been used in carcinogenicity testing, evaluation of such animals and the resulting lines as alternatives to or replacements for the B6C3F~ mouse poses a considerable challenge. For example, the phenotypic characteristics of 2 mouse strains commonly used in developing transgenic lines are summarized below; comparable in-formation on other strains mentioned in this report is given in Table 1. FVB/N inbred mice are commonly used for pronuclear microinjection because of the relatively large size of their pronuclei (125) . These albino mice are not exceptionally aggressive and deliver litters of 6-10 pups. The FVB/N mouse is relatively uncharacterized genotypically and phenotypically, and information on its natural diseases is scarce (84) . Studies of site-specific tumor incidence indicate that aging FVB/N mice have an increased incidence of lung tumors relative to other mouse strains (84) . FVB/N mice exhibit a lower than usual incidence of liver tumors and lymphomas, although they are sensitive to Friend leukemia virus. Female FVB/N mice appear to be susceptible to histiocytic sarcomas, primarily in the uterus.
The inbred C57BL/6 strain is often used for backcrossing knockout mice created by gene targeting in embryonic stem (ES) cells from the inbred strain designated as 129. Unless the knockout line is fully backcrossed, the genetic characteristics of both the 129 and the C57BL/6 strains must be considered when evaluating the biologic responses of such animals. C57BL/6 mice are susceptible to dermatitis with pruritis and exhibit a 10% incidence of congenital abnormalities and a low (7%) incidence of tumors (42) . Among C57BL/6 mice, the incidence of spontaneous lesions increases with age. By 24 months of age, these mice develop a number of hematopoietic neoplasms, including lymphoblastic lymphoma (2-3%), histiocytic sarcoma (4%), and follicular cell lymphoma (17- 20%) (47, 48) . Diabetes and heart abnormalities may be associated with high-fat diets (42) .
Influence of Background Genes on the Phenotypes of Transgenic and Knockout Animals
Although transgenic technology provides the opportunity to more closely examine how certain genes and their products influence specific biologic processes, the dynamic interactions between the introduced DNA construct and the background genes often cannot be fully anticipated. Insertion of the same transgene or the inactivation of a particular endogenous gene (Table 2) in mice   TABLE 2. -Effect of strain on the phenotypes of mice in which specific genes have been introduced or inactivated. For inactivated genes the phenotypic characteristics are given for null/null animals. of different inbred strains may result in the expression of distinct line-specific phenotypes (49) . Such examples illustrate current gaps in scientific understanding of gene regulation and the role of specific gene products in development and growth. The pleiotropic activities of many genes and their products suggest that single gene manipulations may have unforeseen results that could be expressed in a line-specific manner. Moreover, because many biologic response pathways are subject to polygenic control, single gene manipulations may be insufficient for understanding exposure/response relationships.
At least some line-specific effects observed in early studies could be attributed to techniques that resulted in the random insertion of transgenes (17, 74) . With the advent of improved site-specific gene targeting procedures (56, 115) , more mechanistic explanations of line-specific effects are needed. Gene dose effects (114) may contribute to some line-related differences, but such effects often can be identified and accounted for in evaluating such differences.
Factors that likely contribute to differences in transgene activity in different lines include polygenic interactions and differences in gene regulation and expression (62) . Yukawa et al (146) noted that c-myc expression in lymphocytes of 2 different lines of mice resulted in clinically distinct lymphomas (Table 2 ) that were unrelated to line-specific differences in transgene expression or to differences in lymphocyte subpopulation activation. They concluded that the untranslated sequence of the transgene construct may have been involved in translational control processes that differ between lines. Similarly, line-specific microenvironmental factors, eg, growth factors or endogenous viruses, may contribute to interline variability in transgene expression. Conversely, when 2 different approaches to inactivating the epidermal growth factor receptor gene were applied to animals of a single strain (116, 132) , similar effects were observed ( Table 2) .
Transgenic Animal Construction
Transgenic animals have an extra or exogenous fragment of DNA ( Figure 1 ) in their genome and are constructed using 2 general techniques: zygote injection or specific gene targeting of ES cells (17, 20, 58, 74, 115) . Injection or transfection of foreign DNA into either developing zygotes or ES cells results in the integration of the foreign DNA into the host genome. During embryonic development, the foreign DNA becomes incorporated into all cells of the genetically altered animal, thus introducing an inheritable trait that can be used to generate a new mouse line. The construction of DNA vectors and the methods for the characterization and production of transgenic mice are beyond the scope of this article; readers are referred to recent reviews (17, 20, 58, 74, 115, 118) .
Where and how the foreign DNA integrates into the genome is difficult to control using zygote injection. Nevertheless, zygote injection has been used to produce numerous animal lines that are being used in mechanistic studies of genotoxicity and tumor development (1) and for in vivo determination of tissue-specific gene mutation (91) . Other lines constructed by zygote injection contain activated ras oncogenes that are under tissue-specific control. These animals are used to study the role of the ras mutation as an initiating event for multistage carcinogenesis in skin and mammary gland (103, 127) . Other lines bearing activated forms of different oncogenes are being used to study the role of specific oncogene alterations during neoplasia (1) .
Homologous recombination through gene targeting in ES cells permits the development of mice with specifically mutated or inactivated genes (20, 115) . ES cells modified with DNA vectors that integrate at specific sites within a gene can be selectively grown and implanted into donor animals to produce offspring with specifically altered endogenous genes. More than 200 mouse lines have been constructed in this manner (14) (15) (16) , including mice bearing a mutated copy of the p53 tumor suppressor gene (35) . This approach is a powerful one for assessing the involvement of specific gene alterations in tumor development, including chemical-induced tumors.
Transgene Stability
The reproducibility and the consistency of a response in carcinogenicity testing relies on the stable integration and heritable germline transmission of the transgene that is incorporated into the mouse genome. It is critical that the transgene remain stably integrated through the breeding of multiple generations of the transgenic mice. An unstable transgenic line could result in the total loss of the transgene, a decrease or increase of the transgene copy number, alterations in the orientation of the transgene, or mutations within the transgene itself.
In recent studies, a nonresponder phenotype was identified in the Tg.AC line (9, 131, 138) associated with the rearrangement of the zeta (z)-globin promoter region. The nonresponder phenotype exhibits inconsistent papilloma development in response to dermal exposure to the positive control compound 12-O-tetradecanoylphorbol 13acetate (TPA), whereas animals from the same colony previously had been consistently responsive to TPA. Genomic DNA analysis revealed that the mice that had lost the phenotypic response to TPA possessed a heritable genetic alteration within the transgene (129) .
Instability of an integrated transgene does not appear to be a significant problem in most colonies of genetically modified rodents. To the contrary, microinjection techniques and screening protocols provide for lines with stably integrated transgenes (2), yet the possibility exists that a transgenic line could lose its traits over a number of generations. Thus, it is imperative to cryogenically preserve gametes and/or embryos from transgenic animals of known genotype and phenotype to insure that a source of animals with the appropriate transgene(s) would be available for restarting a colony, should that become necessary.
In addition, because transgene stability is critical to the interpretation of the results of a carcinogenicity study, a positive control treatment group might be included in every study. The investigator would be alerted to perform genomic DNA analysis should the positive control group fail to exhibit the expected phenotypic response.
Selection of Animal Lines for Use in Carcinogenicity Testing
Ideally, transgenic animals to be used for carcinogenicity testing should carry genetic alterations that would yield unequivocal evidence of a chemical's carcinogenic potential after no more than several months of dosing. The alteration should not compromise the animals so severely that spontaneously developing tumors occur in sufficient numbers at the same time so as to confound interpretation. Given the observed variation of responses of different rat and mouse strains to chemical carcinogens, the ideal transgenic line should be on the genetic background of a strain known to respond to carcinogens of varying potencies and through various mechanisms of action. Accordingly, the ideal transgenic animal for carcinogenicity testing may require more than 1 gene insertion and/or gene inactivation to facilitate the testing of a diverse array of chemicals. Alternatively, testing in multiple lines, each reflecting different mechanisms of action or responsiveness to certain classes of chemicals (eg, mutagenic or nonmutagenic carcinogens), may be the preferred strategy. As noted by various investigators (4, 13, 32, 33) , there likely are multiple genetic mechanisms that may cause or lead to cancer development, and many as yet unidentified genes may play a role in chemical car-cinogenesis. Final definition of the ideal, universally applicable transgenic rodent for carcinogenicity testing, if it exists, must await the outcome of continuing research.
For any transgenic animal to be utilized broadly for carcinogenicity testing, its key attribute must be an identifiable reaction to chemicals likely to be carcinogenic for humans. Test animal sensitivity and specificity are critical but are more difficult to characterize because of the limited number of recognized human carcinogens. In the context of the conventional 2-year bioassay, it is assumed that because of rodent-specific mechanisms of tumorigenesis, incorrect identification of chemicals as potential human carcinogens (ie, false positives) is more likely to occur with chemicals that do not directly affect DNA (ie, nongenotoxic carcinogens). Evaluation of the suitability of currently available transgenic and knockout animals for carcinogenicity testing is hampered in part by the fact that few nongenotoxic human carcinogens are available for comparative investigations. In the future, animal lines may be developed to specifically address recognized nongenotoxic mechanisms of carcinogenesis.
Transgenic Animal Lines Proposed for Use in Carcinogenicity Testing
Four lines of genetically altered mice have been proposed for use as complements to or alternatives for the conventional 2-year rodent bioassay. The lines proposed bear altered forms of genes that are known to be mutated in certain human cancers (1, 12, 67, 107) . The Tg.AC line carries an activated form of the v-Ha-ras oncogene (80) , the p5311-heterozygote possesses an inactivated copy of the p53 tumor suppressor gene (35) , the rasH2 transgenic mouse bears the human c-Ha-ras gene (142) (143) (144) , and the XPA&dquo;mouse is deficient in nucleotide excision repair (31) .
Tg.AC v-Ha-ras Transgenic Mice. Point mutations among members of the ras gene family are associated with numerous human malignancies, including colorectal and lung cancer and myeloid leukemia (12) . The Tg.AC mouse was constructed by zygote injection of a gene construct containing the z-globin promoter region fused to an activated form of the ras oncogene (v-Ha-ras) and a 3' SV40 polyadenylation signal (81) . The ras oncogene contains 2 point mutations, 1 in codon 12 and the other in codon 59, that are known to be activating (transforming) mutations. The z-globin promoter regulates expression of the mouse embryonic z-globin gene in primitive nucleated erythrocyte precursors. There are 3-10 copies of the transgene per genome, and the transgene is expressed in embryonic blood cells, the hematopoietic fetal liver, placenta, and in low amounts in the adult bone marrow (81) . Wounds obtained during fights among groupcaged males resulted in papilloma formation in the skin at the sites of abrasions.
Leder et al (81) demonstrated that Tg.AC mice develop skin papillomas and squamous cell carcinomas (SCC) following dermal application of the tumor promoter TPA. TPA-induced papillomas and SCC in these animals in the absence of an initiating carcinogen exposure suggested that the initiation/mutation stage of skin multistage carcinogenesis is replaced by the presence of the transgene and that the tumor response can be driven by the application of a promoter. Similarly, topical application of the skin tumor promoters benzoyl peroxide and 2-butanol peroxide induced papillomas within 20 weeks in Tg.AC mice; the incidence of papillomas among unexposed Tg.AC mice was not increased (120) . Thus, Tg.AC mice can be considered to be genetically initiated by the presence of activating mutations in the transgene. The Tg.AC transgene apparently is not constitutively expressed in non-tumor-bearing tissues in the skin but is expressed in papillomas and SCC. Transgene expression can be detected in chemically induced and spontaneous skin tumors and is localized to proliferative areas of the tumors (59) . Although the expression of the v-Ha-ras transgene has been clearly demonstrated in skin papillomas and SCC, activating mutations of the endogenous cellular c-Ha-ras gene have not been observed (102) .
In the case of wound-associated papillomas, expression of the v-Ha-ras transgene was localized to basal epidermal cells (18) , leading the authors to conclude that the biologic response to wounding resulted in transcriptional activation and sustained expression of the v-Ha-ras transgene in the skin. Sustained expression of the transgene in mouse skin may alter normal epithelial differentiation, ultimately resulting in papilloma formation. Detection of v-Ha-ras mRNA and protein occurs concomitantly with hypomethylation of the transgene (19) , suggesting that the introduced z-globin promoter contains sequences that are homologous to those of endogenous promoter regions in the skin, thus permitting the expression of the transgene in skin following hypomethylation. Altered DNA methylation is associated with the aberrant expression of genes involved in tumor development (80) , which suggests that activation occurs through a mechanism that is biologically relevant to both rodent and human cancers. However, the mechanisms responsible for tumor promoter-induced hypomethylation of the v-Ha-ras gene and its expression are uncertain.
In contrast with the induction of the v-Ha-ras transgene observed in skin after physical wounding, chemically induced cytotoxicity in liver and kidney has been shown not to induce v-Ha-ras transgene expression (27) . When male or female Tg.AC mice were treated by gavage for 4 days with cytotoxic doses of chloroform that elevated both hepatic and renal (males only) bromodeoxyuridine labeling, no induction of v-Ha-ras gene expression was seen. However, constitutive expression of the transgene was seen in the kidney. rasH2 Transgenic Mice. The ras family of oncogenes is activated by point mutations, and such activation has been implicated in various human and animal cancers (12) . Because activated ras oncogenes have been observed in 30% of human cancers, transgenic mice containing the human H-ras gene are being evaluated for possible use in carcinogenicity testing (142) (143) (144) .
The rasH2 mouse was produced by microinjection of a human hybrid c-Ha-ras gene construct that has a point mutation in the last intron resulting in the increased expression of the transgene. This transgene does not transform NIH3T3 cells (113) . The rasH2 transgenic mice have 5 or 6 copies of the transgene per genome. By 18 months of age, 50% of these animals develop spontaneous liver tumors, primarily angiosarcomas. In most cases, the transgene was mutated while the endogenous mouse ras gene exhibited the wild-type sequence (113) . The spontaneous tumor incidence is reduced in the F2 generation. rasH2 transgenic mice exposed to numerous genotoxic carcinogens for ~6 months exhibited a more rapid onset and higher incidence of malignant tumors than did control nontransgenic mice (142) (143) (144) . p531&dquo;-Heterozygous Knockout Mice. Mutation of the p53 gene is one of the more common genetic alterations found in a variety of human cancers, including those of the colon, lung, esophagus, liver, and breast (67) . Animals with specifically altered p53 were constructed to examine the biologic function(s) of p53 and its role in tumor development (35, 73) . Such animals may be useful in identifying common steps in the development of tumors, including those associated with exposure to chemicals, in both rodents and humans (61) . Specific gene targeting techniques were used to integrate an inactivated (mutant) form of p53 into 1 of the 2 p53 alleles present in wild-type ES cells. The p53+~-mice are heterozygous for the p53 gene and are considered genotypically analogous to humans who are predisposed to cancers associated with Li-Fraumeni syndrome.
The p53+~mouse is predisposed to spontaneous and chemically induced tumors (61) . The most common spontaneously occurring tumors are osteosarcomas and malignant lymphomas. p53+/-mice exposed to the genotoxic carcinogen dimethylnitrosoamine develop tumors rapidly over a 24-week period. Tumor incidence is increased relative to that observed among unexposed p53+~-mice. The p53-&dquo;mouse appears to be susceptible to tumor induction by mutagenic but not by nonmutagenic carcinogens (128) , possibly reflecting the role that the p53 gene product plays in responding to DNA damage (82) . Significant increases in tumor induction occur after 24 weeks of exposure, and the results are generally consistent with those of the same compounds in conventional 2-year rodent bioassays. p53+'-mice also are susceptible to tumor induction following gamma irradiation (82) . There is a lack of a tumorigenic response among p53+/-mice exposed to phenobarbital for 26 weeks (112) . Respiratory exposure of p53+1-mice to 239PU02 does not increase their susceptibility to tumorigenesis relative to similarly exposed wild-type mice, and p5311-mice are only marginally responsive to beryllium (43) .
XPA-~-Knockout Mice. Humans with the hereditary disorder xeroderma pigmentosum (XP) are predisposed to develop skin cancer where the skin is exposed to sunlight (107) . A defect in the nucleotide excision repair process is responsible for this cancer-prone phenotype (23, 24) . XP patients segregate into 7 complementation groups (XPA through XPG) with members of the XPA group having a gene defect in the DNA damage recognition step of nucleotide excision repair.
Following cloning of the XPA gene by van Oostrom et al (133) , XPA-deficient mice were constructed to study the role of nucleotide excision repair in carcinogenesis (32) . XPA gene inactivation was achieved by replacing exon 3, which encodes the DNA binding domain of the protein, and exon 4. XPA-deficient mice develop normally, are healthy, do not show histologic abnormalities, and are fertile. By 18 months of age XPA-deficient mice have an increased mortality rate and a 15% incidence of hepatocellular adenomas (30) .
XPA-'-mice have an increased susceptibility to ultraviolet light-induced and dimethylbenzanthracene-induced skin cancers (31) . Fibroblasts isolated from XPA-'-mice are deficient in unscheduled DNA synthesis, a measure of nucleotide excision repair (31) , suggesting that these mice mimic the phenotype of XP patients. Exposure to ultraviolet light (UVB) resulted in similar skin cancer responses among wild-type and XPA+Imice, whereas tumors appeared in the XPA-1mice with a latency time that was decreased by a factor of 4.2 relative to that observed among the wild-type animals (8) . Oral exposure of XPA-1-mice to benzo(a)pyrene resulted in the induction of lymphomas that appeared with a shorter latency and a greater incidence than among either XPA+Ior wild-type mice (30) . XPA-1mice exhibit an age-related increase in the incidence of hepatocellular adenomas (30) . Exposure to benzo(a)pyrene resulted in increased levels of benzo(a)pyrene-derived DNA adducts and in increased mutations at both the endogenous hprt gene and the lacZ transgene in XPA-1-IlacZ mice as compared with XPA+J+/lacZ mice, which is consistent with the increased frequency of lymphomas observed in the XPA-1mice (10, 29) .
ISSUES IN EXPERIMENTAL DESIGN

Animal Husbandry
As with studies using conventional laboratory rodents, those using transgenic animals require appropriate husbandry and record keeping. Environmental factors, especially those associated with health status, may affect the expression or the evaluation of the expression of the altered DNA and should be controlled to facilitate the distinction between events influenced by the environment and those attributable to the altered genotype (94) . The expression of a transgene can be altered by infection or by removal of a pathogen from the colony. Certain transgenic phenotypes may result in immunodeficiencies that may compromise the animals' health status (94) . Transgene expression may impair lactation, leading to the failure of pups to thrive or to be weaned successfully, or could influence reproductive performance, thus limiting animal production. For example, female p53 knockout mice often do not survive pregnancy and parturition, thus limiting the breeders' ability to produce p53-1-mice. A program to verify the genotype of the animal line is essential and requires carefully managed breeding programs, accurate record keeping, and confirmatory DNA analysis using polymerase chain reaction or Southern or slot blotting procedures. Phenotypic characterization can sometimes be used to verify the genotype of the animal line.
When using transgenic animals for carcinogenicity studies, the age of the mice and the duration of the study are important. The genetic modification may affect the timing of disease onset and/or the progression of the disease in an age-dependent fashion. Similarly, regulation of transgene expression may be age dependent. Such factors may influence the outcome of carcinogenicity studies or confound their interpretation.
Tumor expression in rodents is qualitatively and quantitatively associated with diet (60, 93) . Many studies have shown that the occurrence and number of tumors are increased and the time to tumor detection is decreased in animals fed ad libitum in the absence of exposure to known or suspected carcinogens. p53+1-animals fed 60% of the ad libitum intake survived longer than did their ad libitum-fed counterparts (69) . Overall ~-85% of both the feed-restricted and the ad libitum-fed animals died of malignancies; the tumor profiles of each treatment group were similar. Preliminary data suggested that the heterozygous animals possess a surfeit of S-phase splenocytes relative to their wild-type littermates and that splenocyte activation and proliferation could result in an increased frequency of mutation, leading to a greater incidence of lymphoma. Restriction of food intake appears to reduce the proportion of S-phase splenocytes among heterozygous animals, possibly explaining their prolonged survival (69) .
In summary, well-characterized, genetically stable animals maintained in a well-defined, controlled environment that is free of pathogens will facilitate the evaluation of transgenic and knockout animals in carcinogenicity studies. Careful attention to the animals' genotype and physical and biologic environment will be conducive to conducting relevant studies that should be reproducible in different laboratories using similar animals under similar conditions (95) .
Experimental Design
Dose Selection and Routes of Administration. A variety of approaches have been devised for the selection of doses to be used for conventional carcinogenicity studies (44) . These approaches reflect the assumption that tumorigenic responses are dose dependent, thus animal studies are performed at doses many times greater than likely human exposures (41) . Although many investigators have questioned this practice, there is no a priori reason to challenge this assumption relative to studies employing transgenic mice. Because smaller group sizes have been used in studies involving p53+1-and Tg.AC mice than in conventional bioassays, the logic for choosing the maximum tolerated dose as the top dose is even more compelling.
Dose selection for carcinogenicity studies in transgenic mice where data are available from a well-designed conventional mouse carcinogenicity study is straightforward, provided that the dosing route is unchanged. If the investigator seeks only to detect a qualitative response, it is probably sufficient to use only the highest dose. However, if the investigator in a conventional study of rats or mice utilizes a different route of exposure, the methods for species-to-species and route-to-route extrapolation are currently inadequate to allow for the selection of a single dose. Even different strains of mice may give variable responses. If a single dose is incorrectly chosen and is too high, it will be obvious from the results. However, if the selected dose is too low, a false-negative result may be obtained. Furthermore, if the investigator seeks to confirm the shape of the dose-response curve, additional doses should be used.
The International Conference on Harmonisation (70) identified 5 approaches to selecting doses for use in carcinogenicity studies: toxicity-based endpoints (ie, the maximum tolerated dose), pharmacokinetic endpoints (eg, a 25-fold area under the curve [AUC] ratio for human and rodent plasma concentrations of a compound), dose limiting pharmacodynamic effects, saturation of absorption, and maximum feasible dose (44) . The 25-fold AUC ratio is specifically designed for studies of nongenotoxic pharmaceutical compounds. There is no obvious rationale for applying different dose selection criteria for carcinogenicity studies to be conducted in transgenic animals.
The guideline (70) also gives general considerations for preliminary dose range studies. A 90-day dose range study is suggested, using the route and method of administration that will be used in the bioassay. In our experience (D.J.-K.), data from preliminary 28-day studies provide an adequate basis for selecting doses to be used during 6-month studies of transgenic animals. Because of the high cost of transgenic mice, wild-type animals of the same genetic background are considered adequate for both dose range and toxicokinetic studies. For example, preliminary studies using C57BL/6 animals would be appropriate in anticipation of conducting a carcinogenicity study in p53+/-mice. Clearly, using wild-type animals in this manner assumes that the presence of the transgene has no significant effect on the metabolism of the compound under study. This assumption may require substantiation.
Any route of administration compatible with a conventional carcinogenicity study, including intraperitoneal and subcutaneous injection, can be used for studies of transgenic animals. Although most studies of Tg.AC mice have involved dermal applications, use of other routes of exposure has been reported (40) . For example, cyclosporin A and methyloacrylamide have been administered by oral gavage and methylphenidate has been given in feed (101). Graves et al (53) showed that dimethyl vinyl chloride, a known human carcinogen, administered by oral gavage induces papillomas in the forestomachs of Tg.AC mice. Thus, the tumorigenic response of Tg.AC mice may not be determined solely by the route of administration. This variation in response is important when evaluating these animals for use in routine carcinogenicity testing, because the dermal route is not relevant to most pharmaceutical agents.
Duration of Exposure/Length of Study. Carcinogenesis studies using p53'1-, Tg.AC, and rasH2 animals have generally been 20-26 weeks in duration. Some data suggest that longer exposures may be required for XPA-deficient animals. For materials giving positive results (tumors) during this interval, duration of exposure is not a concern. However, test duration becomes increasingly important in the absence of tumor formation, ie, a negative study. For p53 knockout animals, extension of stud-ies beyond 26 weeks may not be appropriate because the high background incidence of spontaneously occurring tumors seen at this time could confound the results (61) .
Background tumor incidence does not appear to be a serious concern for studies using Tg.AC mice, and these animals likely can be reasonably evaluated in a 6-month study.
Number of Animals. It has been suggested that using transgenic animals may reduce the total number of animals needed for a carcinogenicity study. Most of the studies conducted to date have involved between 10 and 15 animals/sex/dose; it is unclear whether such group sizes were determined by statistical analysis. Conventional carcinogenicity studies typically involve 50 animals/sex/ dose, which confers an estimated limit of detection of tumor incidence of -10% (78) . If transgenic animals exhibit approximately the same degree of consistency in responses as is seen in wild-type animals, then with fewer animals the limit of detection becomes w-~20%. There is a clear need to incorporate sound statistical principles into the design of carcinogenicity studies using transgenic animals to ensure that the study yields reliable and meaningful results.
Positive and Negative Control Groups. Conventional chemical carcinogenicity studies typically involve 2 or 3 test groups and a vehicle control group; positive and negative treatment control groups generally are not included. This omission presumably reflects the use of a well-characterized test procedure and the expectation that the information return would not justify the use of additional animals and other resources. However, it seems appropriate to include a positive treatment (eg, benzene) control group in studies to evaluate the use of transgenic animals for carcinogenicity testing. Oral gavage with benzene in corn oil (200 mg/kg) produced tumors in p53+1-mice, and application of benzene (-0.5 ml/wk) to the skin of Tg.AC mice resulted in papilloma formation (127, 128) . p-Cresidine and N-methyl-N-nitrosourea (MNU) also have been used as positive control agents. Because carcinogenic chemicals may operate through different mechanisms, the appropriate positive control compound may differ for the various transgenic and knockout animal lines.
Wild-type animals dosed in parallel with their transgenic counterparts have been proposed for use as control animals for carcinogenicity studies. Some potent carcinogens such as p-cresidine, diethylnitrosomine, and 4-[methylnitroso-amino-1 (3-pyridyl)]-1-butanone yielded tumors in both rasH2 transgenic and wild-type animals within 6 months of exposure (144) . In some cases, tumor frequencies were comparable in both groups, but for other compounds the transgenic animals appeared to be more sensitive. These observations demonstrate the value of including wild-type animals in routine testing procedures. Because most compounds developed as pharmaceutical agents are not expected to be potent mutagens (except for certain antineoplastic compounds), these materials are unlikely to induce tumors in wild-type animals over a 6month exposure period.
EVALUATION OF TRANSGENIC AND KNOCKOUT ANIMALS FOR USE IN CARCINOGENICITY TESTING
A plethora of scientific questions need to be examined to better understand the opportunities and challenges associated with transgenic technology and its relevance and application to carcinogenicity testing. In response, a number of collaborative programs have been developed to explore many of these issues.
National Programs
During 1996, the US National Institute of Environmental Health Sciences (NIEHS) initiated an informal, international scientific partnership to provide for collaboration and cooperation in the evaluation of certain currently available transgenic animal lines. Although each participating institution has specific scientific interests and goals, a collective effort to use similar methods and to develop a database of chemicals tested in common has been pursued. Participants include the NIEHS and NTP in partnership with Boehringer-Ingelheim Pharmaceutical Co, the Central Institute for Experimental Animals (CIEA, Japan), and the National Institute of Public Health and Environment (RIVM, The Netherlands).
This initiative focuses principally on the evaluation of the p53+1-and Tg.AC lines and, in collaboration with CIEA, on evaluation of rasH2 transgenic animals. To date, the NIEHS has evaluated 24 chemicals in the Tg.AC line and 14 in the p53+1-line (129) . The NTP has evaluated 12 additional substances in the Tg.AC and p53+1-lines (40) . Seven agents that are undergoing conventional bioassays at the NTP are simultaneously being tested in both the Tg.AC and p53+~-lines. The CIEA is evaluating approximately 25 chemicals and drugs in rasH2 mice (142) ; at least seven of those also are being tested in Tg.AC and p53+1-animals. Boehringer-Ingelheim is collaborating with the NIEHS in the evaluation of 3 agents in common and others of specific interest. The RIVM is developing the XPA-~-line (31) and has selected several chemicals/drugs for use in the initial phase of the evaluation (134) .
ILSI Health and Environmental Sciences Institute
Collaborative Research Program
Interest in better evaluating the utility of transgenic and knockout animals for carcinogenicity testing and the willingness of the regulatory authorities to accept such data as part of the safety assessment process for pharmaceuticals (71, 72) has stimulated international interest in gaining experience with and a greater understanding of the strengths and limitations of the various animal lines. Transgenic animals generally are incompletely characterized, and scientific consensus does not yet exist regarding their most appropriate application, eg, as screening tools, to assist in prioritizing further testing, to enhance understanding of carcinogenic mechanisms, or to provide data for risk assessment.
In the interest of compiling a sufficiently large and robust database on the responses of transgenic and knockout animals to chemicals, the ILSI Health and Environmental Sciences Institute is coordinating a multilaboratory international evaluation of the 4 transgenic lines de- (108) . A total of 21 compounds, mostly pharmaceutical agents, for which there are reliable 2-year rodent bioassay data and human data are being evaluated in each line. These compounds include known and suspected human carcinogens, rodent carcinogens considered to be noncarcinogenic in humans, and noncarcinogenic agents. In a number of cases, there is relevant mechanistic information available to facilitate interpretation of the results in the context of human health risk assessment. Good Laboratory Practices-compliant procedures have been developed for each line, and sources of test materials have been standardized. A number of the chemicals will be evaluated in multiple laboratories and by various routes of exposure. For most compounds, dose range studies are being conducted in the various lines. Quality control, histopathologic, and statistical reviews are integral to the overall process. These studies are being closely coordinated with those of the NIEHS/NTP, CIEA, RIVM, and others such that over 100 studies will be part of the database that is expected to be completed during 2000.
DATA ANALYSIS AND INTERPRETATION Tumor Profiles and Tumor Incidence
To understand and interpret the relevance of chemicalinduced tumors in transgenic animals, it is first necessary to appreciate the types and incidences of spontaneously occurring tumors in these animals. The tumors found in untreated mice of the p53 knockout, XPA-deficient, and Tg.AC and rasH2 transgenic mouse lines are tabulated in Tables 3-6. Donehower et al (35) reported that p53-1-mice commonly develop malignant lymphomas in high incidence (77°l0) by 6 months of age, but sarcomas are less common (46%). In p53+1-mice, sarcomas are more common than lymphomas among both male and female animals of all ages, but especially among animals >8 months of age (Table 3) . T-cell lymphomas arise in the thymus, and Bcell lymphomas may arise in the lymph nodes and spleen.
Sarcomas may arise in various soft tissues and include osteosarcomas, hemangiosarcomas, and rhabdomyosarcomas. The sarcomas are highly invasive but often do not metastasize. Carcinomas of lung, salivary gland, Hardarian gland, and other tissues are found in low frequen- cies. Because p53-'or p53+1-mice develop spontaneous tumors in many tissues, they could be very susceptible to multiorgan carcinogenesis induced by chemicals or other agents. p53+1-mice <6 months of age have few spontaneous tumors, and those found are usually lymphomas and sarcomas. Thus, if a chemical has a particular target site other than the hematopoietic tissues, the background incidence of these tumors in untreated control animals should not confound study evaluation and analysis. Few chemicals are known to cause sarcomas. Although sensitivity to carcinogens may be related to inactivation of 1 p53 allele (34), other (background) genes may play a role in the observed responses. For example, p53-1-mice created on a C57BL/6 background may be resistant to certain types of carcinogens, especially those involving the liver. Although not well understood, 2 genes have been associated with resistence to hepatocarcinogenesis (104) and could influence the response of p53-1-and p53+'-mice on this background to exposure to hepatic carcinogens. Moreover, Venkatachalam et al (135) observed that among p53+'-mice reduced p53 protein synthesis was sufficient to promote tumorigenesis, ie, inactivation of the wild-type p53 allele was not a prerequisite for tumor formation.
Ras transgenic mice (Tg.AC and rasH2) have various incidences of several types of tumors at 6-12 months of age (Tables 4 and 5) (21, 40, 83, 92) . At I year of age, Tg.AC mice have up to a 35% incidence of odontogenic tumors (83, 141) . Other spontaneous tumors include forestomach (7.4-10.3%) and skin (3.8%) papillomas and lung adenomas (1.6-4.3%). Spontaneous tumor incidence in rasH2 transgenic mice is low at 6 months of age and includes lung adenomas (6.7%), hemangiosarcomas of the spleen (3.9%), and papillomas of the forestomach (2.8%) (92) . XPA-deficient mice (Table 6 ) have a 15% incidence of hepatocellular adenomas at 15-20 months of age (30) .
Molecular Analysis of Tumors in Transgenic Mice
The p53+'mouse has 1 functional wild-type allele and 1 inactivated or null allele. Inactivation of the remaining wild-type p53 allele by mutation or loss could give a selective growth advantage to affected cells and result in shortened tumor latency or genetic instability. Similarly, tumor latency may be influenced by the amount of protein produced by the wild-type allele (135) . A strategy for analyzing the molecular changes in the wild-type p53 allele of chemical-induced cancers in the hemizygous mice might include the following steps. First, consideration should be given to performing a Southern blot analysis of the genomic DNA (35, 76, 77) . With appropriate probes, a Southern blot analysis is the most precise and efficient method for determining intragenic or intrachromosomal alterations and loss over extended genetic sequences due to the specificity of the complementary probe for the wild-type gene sequences. Pairwise comparison of representative genomic DNA samples from nontumor (ear or tail) and tumor sites may be used to simultaneously demonstrate the expected genotype and the loss of the wild-type allele (38) .
Tumors of sufficient size (-4-5 mm diameter) should be obtained when possible for histopathologic examination and for molecular analysis. If loss of heterozygosity (LOH) or of the wild-type allele is frequently demonstrated in the tumor DNA, no further analysis is required because neither p53 mRNA nor p53 protein may be observed. Conversely, if infrequent or no LOH or wild-type allele loss can be demonstrated, additional analysis will be required to determine if the wild-type p53 allele has been inactivated. Mutations in the p53 allele may be detected in a number of ways, including single-strand conformational polymorphism analysis (68) , followed by sequencing of the polymorphisms for mutation identification (52) . In the absence of polymorphisms or mutations identified by sequencing, other strategies and methods requiring RNA and/or protein analysis will be necessary to ultimately determine the mode or mechanism of p53 inactivation (46) . Molecular analysis of tumors from rasH2-deficient mice can provide important insights into observed tumorigenic responses. For example, Ando et al (6) noted activating mutations in codon 12 of the rasH2 transgene in MNU-treated mice. Activating mutations were also observed in codon 61 of the same transgene in spontaneous tumors from aged rasH2 mice (113) . Among aged rasH2 mice exhibiting different types of liver lesions, mutations of codon 61 of the endogenous mouse gene were observed in the hepatocellular carcinomas but not in hepatic hemangiosarcomas; codon 61 of the human transgene was mutated (65) . The absence of mutations in foci and adenomas suggested that the mutations may occur relatively late in the neoplastic process.
Given the absence of clear understanding of the mechanisms associated with tumorigenesis in Tg.AC mice, molecular analysis of tumors arising during carcinogenicity studies may be of limited value. Molecular analysis of tumors from XPA-deficient mice may also be of limited value because the target gene(s) for the enhanced mutagenicity expected to occur due to the XPA-1-nucleotide excision repair-deficient phenotype are not known. The endogenous ras and p53 genes may be likely targets for mutation in XPA-1mice depending on the target tissues for tumorigenesis and the availability of screening techniques for mutations in these genes.
Statistical Analysis
Conventional statistical tests likely can be applied to most data derived from carcinogenicity studies in transgenic mice. Studies of p53+/-, Tg.AC, rasH2, and XPAdeficient lines have provided tumor incidence data from both treated (multiple doses) and concurrent control groups. In addition, the Tg.AC line can provide data on time to tumor development (for tumors 1 cm in size) and multiplicity of tumors per mouse. Because both treatment and observation periods are relatively short (26 weeks), survival generally will not be a problem in the absence of overt toxicity. Therefore, it is likely that Fisher's exact test can be used for pairwise comparisons and that the Cochran-Armitage test can be used for trend analysis (40) . For studies having increased mortality, survival-adjusted methods may be needed to evaluate tumor incidence data (64) . In (25, 126) to evaluate the time of initial tumor onset for each animal.
In addition, they used Jonckheere's (75) trend test to compare the maximum number of skin papillomas per mouse (tumor multiplicity) with pairwise comparisons made using the Mann-Whitney U-test (117) . Analytic procedures based on statistical models for tumor onset and multiplicity (39) are under development.
IMPLICATIONS FOR RISK ASSESSMENT
Analysis of tumor incidence data for different tumor sites will determine whether a test agent elicits a positive (tumor) response. Upon completion of these analyses, the more difficult task remains of determining the biologic significance of the data for human health hazard identification and risk assessment. The single most important factor in this evaluation is the credibility of the assay itself based on its past performance in tests of compounds whose carcinogenic potential is well characterized. To the extent that any 1 animal model exhibits a high degree of sensitivity and specificity in identifying compounds be-lieved to have carcinogenic potential in humans, data from that model will be critical to the overall weight-ofevidence evaluation of all toxicologic data for that chemical. Conversely, if prior experience indicates that the assay yields data of questionable significance with respect to human health risk assessment, such data are less likely to play a critical role in the overall weight-of-evidence evaluation.
In the case of transgenic and knockout animals, limited past performance data preclude such assessments. Should p53+~-mice be found to respond very specifically only to potent genotoxic carcinogens but lack the sensitivity to detect other known human carcinogens of weak or equivocal genotoxicity, a clear positive (tumor) response would provide compelling evidence of a potential hazard to human health. A negative response would be less conclusive and would require careful consideration of any other genotoxicity or tumorigenicity data available for that compound. Conversely, if dermally exposed Tg.AC animals are found to be overly sensitive to toxic or proliferative stimuli (eg, full thickness skin wounds) but lack specificity for detecting compounds with well-documented carcinogenic potential, positive results would carry considerably less weight in the overall evaluation of the toxicity of a test compound. A negative result in Tg.AC mice may be a better indicator of a lack of carcinogenic potential. Clearly, future use and acceptance of carcinogenicity data from transgenic and knockout animals for risk assessment will depend on the cumulative experience with the assays, ongoing evaluations of each animal line, and the accrual of scientific knowledge about the mechanisms of carcinogenesis in both animals and humans.
Routine use of transgenic animals in carcinogenicity testing will be contingent upon demonstration of their ability to predict human cancer hazards with a reasonable level of accuracy. Such demonstrations are predicated upon several important questions. First, what level of accuracy in risk prediction is required to adequately protect public health and can reasonably be achieved by these models? The required level of accuracy will depend, in part, on the role of the assay in the overall testing strategy, ie, whether testing in transgenic animals will supplement 1 or more conventional bioassays or will be considered a stand-alone study. Is it acceptable to use transgenic animals to provide only a qualitative prediction of the carcinogenic potential of a compound at any human tissue or should transgenic animal models be expected to predict specific cancer site(s) in humans? Can tumor data from transgenic animals be used for quantitative risk assessment and be extrapolated to the typically lower dose levels associated with human exposures? Future carcinogenicity studies also may need to address variability in human susceptibility to cancer as more is learned about the role of human cancer susceptibility genes in risk determination. Can transgenic animals be used to estimate differing degrees of risk for specific human subpopulations with varying susceptibilities to specific types of cancers? If so, when and in what situations will it be beneficial and cost effective to attempt this type of testing of the carcinogenic potential of chemicals?
Site Concordance
As a testing strategy, it is probably sufficient that transgenic animals provide only a qualitative prediction of the human carcinogenic potential of a compound. The assumption is that, for any given animal model, tumor induction occurs as a result of mechanisms known or believed to be important in human carcinogenesis, eg, mutations in oncogenes or tumor suppressor genes. Furthermore, accurate prediction of the site of carcinogenicity in humans is not a standard that conventional 2-year bioassays are expected to meet. Although there is a relatively high degree of site concordance between target organs for pharmaceutical agents known to be carcinogenic in humans and the occurrence of tumors at the same site in at least 1 species of laboratory animal (89), there are usually more different sites affected in the animals. These results may reflect the relative insensitivity of epidemiologic methods for identifying sites of tumor induction by chemicals in humans, the greater exposure levels used in animal testing, and/or species-related differences in target organ specificities.
Most human carcinogens act as multisite, multispecies carcinogens in rodents. Thus, when positive results occur in a rodent bioassay with a compound of unknown carcinogenic potential in humans, there is some probability that 1 of the affected target organs may correspond to a target organ in humans. Given the often high and strainspecific incidence of spontaneous tumors in rodents, confidence in such a prediction is usually high only when treatment-induced tumors occur at sites with a very low spontaneous tumor incidence in control animals.
Although it is probably sufficient that transgenic animals provide only a qualitative prediction of carcinogenic potential in humans without predicting site specificity, toxicologic science clearly would be improved if such animals could accurately predict site-specific effects in humans. It is already apparent that the animal lines discussed here are unlikely to do so. Given that the pattern of tumor site specificity for some chemicals differs among species, it is perhaps unrealistic to expect transgenic mice to exhibit a greater degree of site concordance with humans than has been observed in conventional rodents in bioassays with known human carcinogens. The genetic background of the host strain can influence the site of tumor formation in transgenic mice (36) , and the limited duration of studies in transgenic mice (26 weeks) likely results in fewer tumors attributable to the promotion or enhancement of spontaneous background tumors. Although there is some expectation that sites of tumor formation in transgenic mice may be indicative of those sites in humans where the transgene (oncogene or tumor suppressor gene) is known to be involved in tumor initiation or progression, there is little evidence to support this idea. For example, although ras gene activation plays a major role in liver tumorigenesis in some mouse strains (45, 86, 111) , there is little evidence for ras activation in human liver tumorigenesis (124) . At other sites, eg, the lung, there is some evidence for a concordant role for Kras activation (28, 85, 109, 110, 121, 145) . Although, there is substantial evidence of p53 involvement in hu-man liver tumorigenesis (55) , there is little evidence for its role in mouse liver tumorigenesis (52, 79) . The degree of site concordance may be poorest for sites such as the mouse liver, where specific hepatocarcinogenesis susceptibility genes are believed to play a dominant role (37, 104) .
The expectation of a greater or lesser degree of tumor site concordance varies among the transgenic lines. Expectations are greater for mechanism-based models such as the P53+1-, rasH2, and XPA-1-mice and lowest for Tg.AC mice because the degree of systemic exposure to a compound applied dermally clearly limits the likelihood of concordance at sites other than skin. However, various nonskin tumors arise in Tg.AC mice exposed to carcinogens by other routes of administration. The proposed utility of Tg.AC mice for risk assessment stems from data suggesting that carcinogenic and/or tumor-promoting chemicals with different mechanisms of action and target tissue specificity may share a common activity, eg, activation of expression of an oncogenic transgene driven by a z-globin promoter in a subpopulation of epidermal cells localized to hair follicles that results in the formation of skin papillomas (120, 127) . Although there is limited evidence relating constitutive or inducible expression of the transgene and susceptibility to tumor formation at other sites, eg, jaw, spleen, salivary gland, and mammary gland (21, 81, 120) , experience suggests that there will not be a high degree of concordance of tumor sites between these animals and humans regardless of whether dermal or oral routes of exposure are used. Because v-Ha-ras transgene expression is regulated by a fetal z-globin promoter (81) that is most likely regulated by tissue-specific transcription factors or enhancers, there is no basis for assuming that a chemical's ability to activate transgene expression and induce tumors at a particular site will be a good predictor of the site(s) of tumor formation in humans.
The rasH2 mouse was designed to achieve high level expression of the normal H-ras protooncogene product (protein) in a variety of tissues by using the normal human H-ras promoter sequence (113) . This allows for the possibility that the transgene might enhance susceptibility by any of several mechanisms, including mutagenesis at specific activating codons in 1 of the copies of the transgene (65) . Alternatively, cooperativity between the transgene-mediated overexpression of normal human H-ras and second &dquo;hits&dquo; by the test chemical on endogenous mouse genes (eg, myc or p53) could result in transformation. Given the enhanced expression of H-ras in multiple tissues and the possibility of enhanced tumor susceptibility by more than 1 mechanism, rasH2 mice are expected to exhibit a relatively high degree of site concordance. Yamamoto et al (142, 143) noted that tumors in these animals occur predominantly at 4 sites; forestomach (papilloma and carcinomas), skin (papillomas and carcinomas), lung (adenomas and adenocarcinomas), and spleen (hemangiosarcomas). Susceptibility to colon tumorigenesis is also enhanced in rasH2 mice (144) . Ras oncogene activation is believed to play a role in human colon cancer (12) . Other tumor sites where ras gene activation plays an important role in human tumorigenesis, eg, bladder and pancreas, do not appear to be enhanced targets for chemical carcinogenesis in rasH2 mice (144) . Expectations of site concordance are confounded because there are 3 ras protooncogenes (H-ras, K-ras, and N-ras); K-ras and N-ras are more frequently involved in human carcinogenesis than is H-ras (12) .
Expectations for a high degree of site concordance were greatest for the p53+1-mice because p53 mutations have been found in up to 50% of human tumors at many sites (55) . However, these expectations were tempered by the more limited role for p53 gene inactivation in spontaneous and chemically induced tumors in nontransgenic mice (52, 66, 79) . The rapid development of a variety of tumor types in p53-1-mice (35) demonstrated the importance of normal p53 function. The preponderance of lymphomas and sarcomas in these mice also raised doubts as to the relevance of this model for epithelial cell-derived tumors and about the degree of site concordance with human tumors. Such findings may be less a reflection of the resistance of certain tissues to tumorigenic enhancement by p53 inactivation than a reflection of the rapid development of the lymphomas and sarcomas that kill the animals before effects in other tissues become evident. For example, the relatively specific bladder tumorigen, p-cresidine, produced bladder tumors in p53+1mice (127) .
As data from the various evaluation studies with different chemicals become available and provide more insights about site specificity, a clearer picture of the degree of site concordance and predictability attainable with transgenic animals should emerge. However, this picture likely will be complicated and associated with many uncertainties.
Quantitative Risk Assessment
Quantitative cancer risk assessment often involves mathematic extrapolation from tumorigenic effects seen in a significant fraction of test animals exposed to relatively high doses of a chemical to predict the occurrence of similar effects among humans exposed to the same compound at much lower doses (130) . This process has many attendant uncertainties and has been the subject of much critical discussion. The use of animals that are genetically predisposed to tumor induction for carcinogenicity testing introduces a new level of complexity to this process. Because transgenic and knockout animals are engineered for increased susceptibility to cancer induction, incorporating the results of such studies into quantitative risk assessments may lead to an overestimation of risk to &dquo;normal&dquo; individuals in the human population because of downward shifts in animal-derived dose-response curves. Evidence for such a shift requires comparison of dose-response relationships for studies of equivalent duration in both transgenic and nontransgenic mice over a wide range of doses. Such studies would have to be sufficiently long (ie, 2 years) to allow for tumor development in the nontransgenic mice, although studies of such duration would be confounded by spontaneous tumor development in the transgenic mice. Carcinogenesis studies in transgenic mice are typically of 26 weeks duration, which is generally insufficient for expression of compound-associated tumorigenic effects in nontransgenic mice. Cancer bioassays performed in transgenic animals are characterized by a reduced latency period because of an acceleration of the tumor response relative to that observed among nontransgenic animals. Because of the accelerated tumorigenesis, it is unclear whether the predicted shifts in the dose-response curve for transgenic animals are effectively nullified by the 75% reduction in study duration (ie, from 24 months to 6 months). Studies by Tennant et al (127) of p53 knockout mice exposed to either of 2 genotoxic carcinogens (p-cresidine and 4-vinyl-1-cyclohexene diepoxide) appear to support this contention. Both compounds were tested at cumulative weekly doses equivalent to those used in the 2-year bioassay in B6C3F1 mice. Tumor incidence at equivalent daily doses was greater among the B6C3F1 mice after 2 years of exposure than among p53+/-mice after 26 weeks of exposure. Based on the total dose administered over the entire study, the dose-response curves for the transgenic animals were shifted downward, indicating increased sensitivity.
In theory, the sensitivity of any transgenic animal bioassay may be &dquo;adjusted&dquo; to approximate that of a lifetime bioassay in nontransgenic mice by choosing a study duration that gives an equivalent tumor response. Although impractical, this adjustment would be required for each transgenic animal line, with the appropriate duration perhaps differing for different compounds with different mechanisms of action. Moreover, it would be preferable to compare the dose-response relationships for the transgenic animals to those for humans. Although these comparisons may be possible for radiation and certain chemotherapeutic agents, they would be difficult given the dearth of quantitative data on human exposure to known human carcinogens. The most useful data for estimating the relative sensitivity of the various transgenic lines will likely come from studies similar to those of Tennant et al (127) (127) noted that the low incidence of spontaneous tumors in transgenic animals at the end of 6-month studies might offer important advantages for quantitative risk assessment. For example, detection of small effects at low doses in conventional 2-year bioassays is complicated by the high and variable incidence of spontaneous tumors; such confounding factors are unlikely during the shorter duration studies in transgenic animals. This may allow for more accurate determination of the shape of the dose-response curve at lower doses that are more relevant to actual human exposures. However, the small number of animals used (10-15 animals/ sex/treatment group) limits the sensitivity of such studies.
In recent years there has been considerable interest in using mechanistic information to refine the quantitative risk assessment process for carcinogenic effects. The rapid accrual of information about the molecular mechanisms of activation and inactivation of genes responsible for tumor initiation and progression has led to the creation of the transgenic animals discussed here. Mechanistic information also has been incorporated into biologi-cally based dose-response models that seek to mathematically describe and simulate the various processes underlying tumor development (97) (98) (99) . The rate of occurrence of mutations in 1 or more oncogenes and/or tumor suppressor genes is thought to determine the size of the pool of initiated cells in a particular tissue. The product of the affected gene(s) may further regulate the clonal expansion of the initiated cells by influencing the rates of cell division, cell differentiation, or cell death for each clone. Specific sequences (or combinations of sequences) may be involved in disregulation of certain genes. For example, activation of the c-myc oncogene is thought to drive cell proliferation, which may be offset by a high rate of apoptosis (5) . Subsequent activation of ras or inactivation of p53 may decrease the rate of apoptosis and enhance the rate of clonal expansion. In this model, p53 inactivation may act as a double-edge sword by conferring a hypermutable phenotype on the initiated cell, leading to global genomic instability, and by enhancing the rate of conversion of intermediate cells to a more malignant phenotype. Such a scenario is consistent with the suggestion of Mao et al (87) that p53 inactivation might not represent a distinct stage in the multistage process of carcinogenesis but rather loss of a &dquo;caretaker&dquo; gene function that modifies the rate of mutation in the critical &dquo;gatekeeper&dquo; genes that ultimately control the progression of proliferative lesions to more advanced stages.
This line of reasoning suggests that the different oncogenes (eg, ras, pim-1 ), tumor suppressor genes (p53), and DNA repair genes (XPA) that are expressed or inactivated in the transgenic animals discussed here may have very different quantitative effects on 1 or more of the rate constants that drive biologically based dose-response models. Extrapolations based on dose-response data for a given transgenic animal line likely will overor underestimate human risk, depending on the gene involved and on the manner in which the chemical interacts with that gene or with other cooperating oncogenes. For example, a chemically induced point mutation in the normal p53 allele in the p53 heterozygous mouse may have variable effects depending on the location of the mutation. Complete loss of the normal allele by exposure to clastogens or aneuploidogens might be expected to have more predictable and potent effects. Similarly, for rasH2 animals, a point mutation at a critical codon within the overexpressed normal human H-ras gene may have a more or less potent effect compared with the activation of a cooperating oncogene, eg, c-myc, by a different mechanism, eg, hypomethylation. Thus, it may be just as difficult to assess the accuracy of risk extrapolations using biologically based dose-response models when using data from transgenic animals as it is when using data from conventional studies when there is little understanding of the underlying mechanisms. Comparison of empirical data from transgenic and conventional animal bioassays may be more productive.
Risk Assessment for Susceptible Human Subpopulations
Growing recognition of the extent to which cancer susceptibility is under genetic control (1, 90) raises the issue of whether transgenic animal bioassays can and should be used to estimate risk for specific human subpopulations with greater susceptibility to certain types of cancers. With the recent discovery and characterization of susceptibility genes for breast (BRCA-1, BRCA-2), colon (MutS, MutH), kidney (VHL, Wilm's), skin (XP genes), eye (Rb), and other cancers, there is a growing appreciation for the extent to which human cancer risk is attributable to the individual's genotype (136) . Cancer susceptibility genes includes those that regulate phase I and/or phase II metabolism of xenobiotics that can lead to the activation of procarcinogens and the detoxification of DNA-reactive electrophilic metabolites. Transgenic animals expressing various metabolic phenotypes are being introduced at a rapid rate. However, it is unrealistic to expect to test new chemicals in multiple models, given the costs and resources required. Before such testing could be undertaken, it would be prudent to prioritize testing options based on the number of affected individuals in the human population and the probability that they are at increased risk. It might be practical to selectively test chemicals in specific transgenic animal lines when the magnitude of the problem indicates a favorable benefit-cost ratio. For example, a chemopreventive medication targeted for use in individuals with a genetically based high risk of developing breast cancer might be tested in a transgenic animal line with enhanced susceptibility to mammary gland tumorigenesis to assess the degree of risk associated with the prophylactic treatment. Such situations may arise with increasing frequency as more transgenic lines become available and as more chemopreventive treatment strategies are developed for specific cancers.
SUMMARY/CONCLUSIONS
The development of lines of transgenic animals that express a variety of oncogenes, tumor suppressor genes, and other genes thought to be involved in carcinogenesis provides a unique opportunity to improve scientific understanding of carcinogenic mechanisms. Human and animal data suggest that the specific activation or inactivation of certain genes may be critical events in pathways leading to various types of cancers, yet it is apparent that no single common pathway is likely to explain all cancers. The ability to dissect each pathway will be a function of knowledge gleaned from in vivo and in vitro studies of molecular mechanisms. Transgenic animals are playing a critical role in the in vivo studies.
Knowledge gained through such studies has influenced and will continue to influence the design, conduct, and interpretation of studies to determine the potential of drugs and other chemicals to cause cancer. Such information is essential in assessing whether exposure to such agents poses a cancer risk to humans. Hence, there is broad interest in determining whether carcinogenicity testing in transgenic animals will yield information that can enhance current human health risk assessment practices. Because transgenic technology affords the opportunity to exploit known or suspected modes of carcinogenic effects, carcinogenicity testing in transgenic animal lines has been suggested as a means of increasing the relevance and accuracy of cancer risk estimates. Whether this expectation is realized will depend on rigorous scientific examination of individual animal lines.
In addition to the scientific value associated with carcinogenicity testing in transgenic animals, such testing provides the opportunity to reduce the time required and the resources needed to assess the carcinogenic potential of chemicals. By reducing the development period for new drugs and chemicals and by potentially yielding more reliable and more relevant data, carcinogenicity studies in transgenic animal lines could result in the more rapid release of beneficial drugs and chemicals into the marketplace. Such testing could result in increased confidence in the safety of those products by test sponsors, the regulatory community, and the public. The potential of studies in transgenic animal lines to result in fewer false-negative and false-positive outcomes and fewer indeterminate results would facilitate the risk assessment process. Clearly, such a scenario would benefit the public as well as the pharmaceutical and other industries while facilitating the regulatory review process. The use of transgenic animals for carcinogenicity testing must be thoroughly evaluated by examining their responses to well-characterized reference compounds under standardized conditions in many laboratories. Only through rigorous evaluation will the requisite experience and confidence be gained that will permit the widespread use of these animals for testing in support of regulatory assessment of novel or previously untested chemicals.
Coordinated international programs are intended to provide the &dquo;real world&dquo; data necessary for judging the potential usefulness of some of the currently available transgenic mouse lines for routine carcinogenicity testing.
This overview highlights a variety of issues that should be considered in evaluating the potential use of transgenic animals for carcinogenicity testing and human cancer risk assessment. Of the currently available transgenic mouse lines being evaluated, it is unlikely that a single line will be appropriate for all testing situations; such an expectation may be unrealistic. Nevertheless, conceptually and mechanistically, each of these lines possess characteristics reflective of current understanding of certain aspects of carcinogenesis and, thus, should permit a reasonable assessment of the applicability of this technology to routine carcinogenicity testing. Moreover, information obtained from these studies will likely lead to the development of better animal models in the future, while contributing to the scientific understanding of carcinogenesis and cancer risk assessment.
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